Sumatriptan

Overview

Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. It is taken orally, intranasally, or by subcutaneous injection. Therapeutic effects generally occur within three hours. Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist (triptan).[1][2][3] WP

The drug acts as a serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptor agonist and its common side effects include chest pressure, fatigue, vomiting, tingling, and vertigo. Serious side effects may include serotonin syndrome, heart attack, stroke, and seizures. With excessive use, medication overuse headaches may occur. It is unclear if use during pregnancy or breastfeeding is safe. The mechanism of action is not entirely clear. It is in the triptan class of medications.[3–6] WP

Sumatriptan was patented in 1982 and approved for medical use in 1992. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 107th most commonly prescribed medication in the United States, with more than 6 million prescriptions. It is also available as the combination product sumatriptan/naproxen.[1][2][7–11] WP

Uses, dosage and effects

Medical uses

Sumatriptan is indicated for the acute treatment of migraine with or without aura in adults; or the acute treatment of cluster headache in adults.[2] WP

Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. Injected sumatriptan is more effective than other formulations.[12][13] WP

Oral sumatriptan can be used also in the treatment of post-dural puncture headache.[14] WP

Risks and side effects

Contraindications

Contraindications of sumatriptan include history of coronary artery disease (atherosclerosis) or coronary artery vasospasm, Wolff–Parkinson–White syndrome or other cardiac accessory conduction pathway disorders, history of stroke, transient ischemic attack, or hemiplegic or basilar migraine, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, use of another triptan or ergot-related medication within the last 24 hours, concomitant or recent use of a monoamine oxidase inhibitor (MAOI), hypersensitivity to sumatriptan, and severe hepatic impairment.[2] WP

Adverse effects

Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation. There are reports of Takotsubo cardiomyopathy and transient amnesia after sumatriptan use.[15][16] WP

The most common side effects reported by at least 2% of patients in controlled trials of sumatriptan (25, 50, and 100 mg tablets) for migraine are atypical sensations (paresthesia and warm/cold sensations) reported by 4% in the placebo group and 5–6% in the sumatriptan groups, pain and other pressure sensations (including chest pain) reported by 4% in the placebo group and 6–8% in the sumatriptan groups, neurological events (vertigo) reported by less than 1% in the placebo group and less than 1-2% in the sumatriptan groups. Malaise/fatigue occurred in less than 1% of the placebo group and 2–3% of the sumatriptan groups. Sleep disturbance occurred in less than 1% in the placebo group to 2% in the sumatriptan group.[2] WP

Sumatriptan has a low abuse potential; however overuse is associated with medication overuse headache. Moreover, prolonged sumatriptan use is associated with pronociceptive effects, resulting in allodynia. This effect's association with medication overuse headache, however, is controversial, due to the fact that animal-model studies are not consistent with typical presentation of this disorder.[17][18][19] WP

Overdose

Overdose in animals produced effects including convulsions, tremor, paralysis, inactivity, extremity erythema, abnormal breathing, cyanosis, ataxia, mydriasis, and injection site reactions. The elimination half-life of sumatriptan in humans is 2.5 hours. The effect of dialysis on sumatriptan levels is unknown.[2] WP

Overdose of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to green, due to the integration of sulfur into the hemoglobin molecule. If sumatriptan is discontinued, the condition reverses within a few weeks.[20] WP

Interactions

Interactions

Concurrent use with other triptans or ergot-containing medications (e.g., ergotamine, dihydroergotamine) within 24 hours can result in additive vasoconstriction. Increased systemic exposure to sumatriptan can occur if used within 2 weeks after a monoamine oxidase inhibitor (MAOI). Cases of serotonin syndrome have been reported with co-administration of triptans and serotonin reuptake inhibitors.[21][22] WP

Pharmacology

Mechanism of action

Sumatriptan is structurally similar to the neurotransmitter serotonin (5-HT) and acts as an agonist of the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors. Sumatriptan's primary therapeutic effect is related in its inhibition of the release of calcitonin gene-related peptide (CGRP), likely through its 5-HT1D/1B receptor agonist action. This has been substantiated by the efficacy of more recently developed CGRP targeting drugs and antibodies developed for the preventive treatment of migraine. How agonism of the 5-HT1D/1B receptors inhibits CGRP release is not fully understood. CGRP is believed to cause sensitization of trigeminal nociceptive neurons, contributing to the pain experienced in migraine.[4][23][24][25] WP

Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases.[26] WP

Sumatriptan does not affect oxytocin or vasopressin levels in humans.[27] WP

Absorption

Sumatriptan is administered in several forms: tablets, subcutaneous injection, and nasal spray. Oral administration (as succinate salt) has low bioavailability, partly due to presystemic metabolism—some of it gets broken down in the stomach and bloodstream before it reaches the target arteries. There is no simple, direct relationship between sumatriptan concentration (pharmacokinetics) per se in the blood and its anti-migraine effect (pharmacodynamics). This paradox has, to some extent, been resolved by comparing the rates of absorption of the various sumatriptan formulations, rather than the absolute amounts of drug that they deliver.[28][29] WP

Distribution

Sumatriptan is a relatively hydrophilic molecule, which may limit its ability to cross the blood–brain barrier and enter the central nervous system. In accordance, early animal studies found lack of indication of central penetration by sumatriptan. This was in contrast to more lipophilic triptans like zolmitriptan, naratriptan, rizatriptan, and eletriptan. For these reasons, it was thought for many years that sumatriptan could not cross the blood–brain barrier in significant amounts to exert central effects.[30] WP

However, in subsequent animal studies, sumatriptan was found to enter the brain and produce centrally mediated effects. Besides animal research, clinical studies have found sumatriptan to produce centrally mediated side effects such as sleepiness, tiredness, thinking difficulty, and dizziness, among others. In addition, sumatriptan has been found to be discernibly psychoactive in human drug discrimination tests, with effects like apathy, sedation, and mild dysphoria. Certain other clinical findings also support centrally mediated effects of sumatriptan.[30] WP

A 2010 literature review concluded that sumatriptan can enter the brain to some minor extent in both animals and humans but that this minor penetration is nonetheless sufficient to cause pharmacological effects. Subsequent research has found sumatriptan given during migraine attacks decreases brain serotonin 5-HT1B receptor binding in humans, with a corresponding receptor occupancy of 16%. However, this apparent occupancy could alternatively be due to increased serotonin release during migraine attacks. In contrast to receptor antagonists, it is notable that agonists require only a low fractional receptor occupancy to produce central effects. Relatedly, the serotonin 5-HT1B receptor occupancy observed with sumatriptan was comparable to that with centrally acting opioids. Besides the clinical findings, further animal studies have found that sumatriptan rapidly enters the brain in spite of its poor lipophilicity and was able to do so more quickly than the benzodiazepine oxazepam.[30–33] WP

Metabolism

Sumatriptan is metabolized primarily by monoamine oxidase A into indol-3-yl-acetaldehyde and then into corresponding carboxylic acid. It is further modified by UDP-glucuronosyltransferase into a conjugate with glucuronic acid. Other pathways are mediated by cytochrome P450 isoenzymes, which give an N-oxide derivative, and N-desmethyl and N,N-didesmethyl forms (the latter can be converted into the aldehyde by monoamine oxidase A). The N-desmethyl derivative can also undergo a reaction with D-cysteine.[34] WP

Elimination

The metabolites of sumatriptan are excreted in the urine and bile. Only about 3% of the active drug may be recovered unchanged.[3] WP

History

History

In 1991, Glaxo received approval for sumatriptan, which was the first available triptan.[35] WP

In July 2009, the US Food and Drug Administration (FDA) approved a single-use jet injector formulation of sumatriptan. The device delivers a subcutaneous injection of sumatriptan, without the use of a needle. Autoinjectors with needles have been previously available in Europe and North America.[36] WP

Phase III studies with an iontophoretic transdermal patch (Zelrix/Zecuity) started in July 2008. This patch uses low voltage controlled by a pre-programmed microchip to deliver a single dose of sumatriptan through the skin within 30 minutes. Zecuity was approved by the FDA in January 2013. Sales of Zecuity have been stopped following reports of skin burns and irritation.[37–41] WP

Legal status

Legal status

In the United States, it is available only by medical prescription. It is available over the counter in many states in Australia. The product requires labelling by a pharmacist and is only available in packs of two without a medical prescription. However, it can be bought over the counter in the UK and Sweden.[42][43][44] WP

Generics

Glaxo patents for sumatriptan expired in February 2009. At that time, Imitrex sold for about $25 a pill. Par Pharmaceutical then introduced generic versions of sumatriptan injection (sumatriptan succinate injection) 4 and 6 mg starter kits and 4 and 6 mg filled syringe cartridges, and 6 mg vials soon after.[45][46] WP

Mylan Laboratories Inc., Sun Pharma, Sandoz (a subsidiary of Novartis), Dr. Reddy's Laboratories, and other companies have been producing generic versions of sumatriptan tablets in 25, 50, and 100 mg doses. Generic forms of the drug are available in US and European markets after Glaxo's patent protections expired in the respective countries. A nasal spray form of sumatriptan known as AVP-825 has been developed by Avanir and is generically available in some countries.[47] WP

Controversy

According to the American Headache Society, "Patients frequently state that they have difficulty accessing triptans prescribed to them." In the US, triptans cost from $12 to $120 each, and more than 80% of US health insurance plans place a limit on the number of pills available to a patient per month, which has been called "arbitrary and unfair."[48][49] WP

Chemistry

Formula

C14H21N3O2S PC

CAS number

103628-46-2 PC

Molar mass (g/mol)

295.40 PC

IUPAC name (computed by PubChem)

1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide PC

SMILES

CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C PC

InChIKey

KQKPFRSPSRPDEB-UHFFFAOYSA-N PC

PubChem CID

5358

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other British National Formulary: BNF 76. 2018
2. Journal / agency Imitrex- sumatriptan injection. 8 February 2023
3. Other Sumatriptan Monograph for Professionals
4. Journal / agency Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?. Pharmacol Ther. June 2018. doi:10.1016/j.pharmthera.2018.01.005 · PMID 29352859
5. Journal / agency Syed YY. Sumatriptan/Naproxen Sodium: A Review in Migraine. Drugs. January 2016. doi:10.1007/s40265-015-0521-8 · PMID 26628293
6. Other Sumatriptan Use During Pregnancy
7. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
8. Other World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). 2021
9. Other Top 300 of 2023
10. Other Sumatriptan Drug Usage Statistics, United States, 2014 - 2023
11. Journal / agency Treximet- sumatriptan succinate and naproxen sodium tablet, film coated. 23 December 2024
12. Journal / agency Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane Database of Systematic Reviews. May 2014. doi:10.1002/14651858.CD009108.pub2 · PMID 24865446 · PMC6469574
13. Journal / agency Dahlöf CG. Sumatriptan: pharmacological basis and clinical results. Current Medical Research and Opinion. 2001. doi:10.1185/0300799039117010 · PMID 12463276
14. Journal / agency Shaat AM, Abdalgaleil MM. Is theophylline more effective than sumatriptan in the treatment of post-dural puncture headache? A randomized clinical trial. Egyptian Journal of Anaesthesia. 1 January 2021. doi:10.1080/11101849.2021.1949195
15. Journal / agency Kelly KM. Cardiac arrest following use of sumatriptan. Neurology. June 1995. doi:10.1212/wnl.45.6.1211 · PMID 7783891
16. Journal / agency Chohan A. Sumatriptan-Induced Takotsubo Cardiomyopathy. Journal of the American College of Cardiology. 7 March 2023. doi:10.1016/S0735-1097(23)03942-6
17. Journal / agency Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR. Psychoactivity and abuse potential of sumatriptan. Clinical Pharmacology and Therapeutics. December 1992. doi:10.1038/clpt.1992.202 · PMID 1333934
18. Other TGA eBS - Product and Consumer Medicine Information
19. Journal / agency Chiarugi A, Buonvicino D. Critical reflections on medication overuse headache in patients with migraine: An unsolved riddle in nociception. Neurobiology of Pain. 1 January 2025. doi:10.1016/j.ynpai.2025.100179 · PMID 40040782 · PMC11876746
20. Other Patient bleeds dark green blood. 8 June 2007
21. Journal / agency DailyMed - SUMATRIPTAN- sumatriptan succinate tablet tablet
22. Journal / agency Drugs for Migraine. The Medical Letter on Drugs and Therapeutics. June 2023. doi:10.58347/tml.2023.1678a · PMID 37266987
23. Journal / agency Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. March 2005. doi:10.1111/j.1468-2982.2005.00836.x · PMID 15689192
24. Journal / agency Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?. Current Treatment Options in Neurology. August 2017. doi:10.1007/s11940-017-0463-4 · PMID 28653227 · PMC5486583
25. Journal / agency Giniatullin R, Nistri A, Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Molecular Neurobiology. February 2008. doi:10.1007/s12035-008-8020-5 · PMID 18459072
26. Journal / agency Ekbom K, Waldenlind E, Richard L, Andersson B, Boivie J, Dizdar N, etal. Treatment of acute cluster headache with sumatriptan. The New England Journal of Medicine. August 1991. doi:10.1056/NEJM199108013250505 · PMID 1647496
27. Journal / agency Chiodera P, Volpi R, Capretti L, Caffarri G, Magotti MG, Coiro V. Different effects of the serotonergic agonists buspirone and sumatriptan on the posterior pituitary hormonal responses to hypoglycemia in humans. Neuropeptides. April 1996. doi:10.1016/s0143-4179(96)90086-4 · PMID 8771561
28. Journal / agency Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache. February 2004. doi:10.1111/j.1526-4610.2004.04030.x · PMID 14756852
29. Journal / agency Freidank-Mueschenborn E, Fox AW. Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan. Headache. June 2005. doi:10.1111/j.1526-4610.2005.05129a.x · PMID 15953294
30. Journal / agency Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man?. J Headache Pain. February 2010. doi:10.1007/s10194-009-0170-y · PMID 20012125 · PMC3452191
31. Journal / agency Deen M, Hougaard A, Hansen HD, Schain M, Dyssegaard A, Knudsen GM, Ashina M. Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding. JAMA Neurol. July 2019. doi:10.1001/jamaneurol.2019.0755 · PMID 31135819 · PMC6547094
32. Journal / agency Holland PR, Sureda-Gibert P, Vila-Pueyo M. Rapid uptake of sumatriptan into the brain: An ongoing question of blood-brain barrier permeability. Cephalalgia. April 2020. doi:10.1177/0333102420905131 · PMID 32000507 · PMC7605048
33. Journal / agency Muzzi M, Zecchi R, Ranieri G, Urru M, Tofani L, De Cesaris F, Panconesi A, Chiarugi A. Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment. Cephalalgia. April 2020. doi:10.1177/0333102419896370 · PMID 31852231
34. Journal / agency Pöstges T, Lehr M. Metabolism of sumatriptan revisited. Pharmacology Research & Perspectives. February 2023. doi:10.1002/prp2.1051 · PMID 36655303 · PMC9849828
35. Journal / agency Humphrey, P. P. The discovery of a new drug class for the acute treatment of migraine. Headache. 2007. doi:10.1111/j.1526-4610.2007.00672.x · PMID 17425704
36. Journal / agency Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, Linn L, Farr SJ. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache. 2009. doi:10.1111/j.1526-4610.2009.01530.x · PMID 19849720
37. Other ClinicalTrialsGov NCT00724815 The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)
38. Other SmartRelief -electronically assisted drug delivery (iontophoresis)
39. Journal / agency Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache. June 2009. doi:10.1111/j.1526-4610.2009.01437.x · PMID 19438727
40. Other Zecuity Approved by the FDA for the Acute Treatment of Migraine
41. Other Teva pulls migraine patch Zecuity on reports of burning, scarring. 13 June 2016
42. Other Poisons Standard June 2017. 18 May 2017
43. Other Press release: First Over The Counter (OTC) migraine pill made available
44. Journal / agency European Medicines Agency. Assessment Report: Sumatriptan Galpharm 50 mg Tablets. 23 November 2011
45. Other GlaxoSmithKline sets out to dupe migraine sufferers with Treximet smoke and mirrors. 24 April 2008
46. Other Par Pharmaceutical begins shipment of sumatriptan injection. 6 November 2008
47. Other LaMattina J. If You 'Want To Make A Good Drug Great' Cost Must Be Factored In. 2 March 2015
48. Journal / agency Minen, M. T., Lindberg, K., Langford, A., Loder, E. Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies. Headache: The Journal of Head and Face Pain. 2017. doi:10.1111/head.13134 · PMID 28691382
49. Journal / agency Bender E. Practice Matters Wide Variation in Triptan Coverage Across Commercial and Government Health Plans. Neurology Today. 7 September 2017. doi:10.1097/01.NT.0000524839.20893.03

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.